Paper Details

  1. Home
  2. Paper Details

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.

Author: CamidgeD Ross, ChenChi-Chang, GorritzMagdaliz, HuangWei-Ti, JahanzebMohammad, LinHuamao M, McGuinessCatherine B, SunKainan, WuYanyu, ZhangPingkuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This retrospective study evaluated real-world brigatinib use in ALK-rearranged non-small cell lung cancer (NSCLC) patients in the US who had previously received other ALK-TKIs. Brigatinib appeared to be effective and well-tolerated, with a median time to treatment discontinuation of 10.3 months. Adherence was high, and most patients achieved the target dose of 180 mg/day. Dose reductions were less frequent than in trials.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world brigatinib utilization in the US post other ALK-TKIs. MATERIAL...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438904/

データ提供：米国国立医学図書館（NLM）

Brigatinib in ALK-Rearranged Lung Cancer: A Real-World Look at Efficacy and Tolerability

This study examines the real-world effectiveness and safety of brigatinib, a targeted therapy for ALK-rearranged non-small cell lung cancer (NSCLC), a disease that can be as unpredictable as a desert sandstorm. This research is like a desert expedition, seeking to understand the practical implications of a promising new treatment.

Brigatinib: A Potential Oasis in the Desert of Lung Cancer

The study finds that brigatinib appears to be effective in treating ALK+ NSCLC, providing patients with a valuable treatment option. It's like discovering a new oasis in the desert, offering a potential source of hope for those battling this challenging disease.

Navigating the Desert of Lung Cancer: A Journey with Careful Monitoring

The study also highlights the importance of careful monitoring for potential side effects and the need for dose adjustments as necessary. It's like navigating a desert with a watchful eye, adapting to the changing conditions and making adjustments as needed.

Dr.Camel's Conclusion

This research provides valuable real-world evidence for the effectiveness and tolerability of brigatinib in treating ALK+ NSCLC. It's like a desert explorer reporting back from the field, providing valuable insights for future expeditions. While further research is needed, this study offers a promising glimpse into the potential of brigatinib to improve the lives of patients with this challenging disease.

Date :
  1. Date Completed 2022-09-08
  2. Date Revised 2022-11-17
Further Info :

Pubmed ID

35781589

DOI: Digital Object Identifier

PMC9438904

Related Literature

Article Analysis
・Effects of brigatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.